BE2014C071I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C071I2 BE2014C071I2 BE2014C071C BE2014C071C BE2014C071I2 BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2 BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004174770 | 2004-06-11 | ||
| JP2004327111 | 2004-11-10 | ||
| US63059604P | 2004-11-23 | 2004-11-23 | |
| US11/150,792 US7378423B2 (en) | 2004-06-11 | 2005-06-10 | Pyrimidine compound and medical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2014C071I2 true BE2014C071I2 (fr) | 2024-10-08 |
Family
ID=35600249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2014C071C BE2014C071I2 (fr) | 2004-06-11 | 2014-11-28 |
Country Status (2)
| Country | Link |
|---|---|
| US (8) | US7378423B2 (fr) |
| BE (1) | BE2014C071I2 (fr) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US6489125B1 (en) * | 2000-05-10 | 2002-12-03 | The Trustees Of Columbia University In The City Of New York | Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor |
| US20040048780A1 (en) * | 2000-05-10 | 2004-03-11 | The Trustees Of Columbia University In The City Of New York | Method for treating and preventing cardiac arrhythmia |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7393652B2 (en) * | 2000-05-10 | 2008-07-01 | The Trustees Of Columbia University In The City Of New York | Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2) |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20060293266A1 (en) * | 2000-05-10 | 2006-12-28 | The Trustees Of Columbia | Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US8710045B2 (en) * | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| WO2006091936A2 (fr) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Procedes permettant d'effectuer la synthese de xanthines a substitution cycloalkyle dissymetrique |
| JPWO2006090930A1 (ja) * | 2005-02-28 | 2008-07-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホンアミド化合物の新規併用 |
| US7704990B2 (en) * | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20080242648A1 (en) * | 2006-11-10 | 2008-10-02 | Syndax Pharmaceuticals, Inc., A California Corporation | COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| SA08280783B1 (ar) * | 2007-01-11 | 2011-04-24 | استرازينيكا ايه بي | مشتقات بيريدوبيريميدين كمثبطات pde4 |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (fr) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Formulations orales pour du picoplatine |
| US20100267779A1 (en) * | 2007-07-23 | 2010-10-21 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| WO2009015203A1 (fr) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Composés novateurs et procédés d'utilisation de ceux-ci |
| WO2009049018A1 (fr) * | 2007-10-10 | 2009-04-16 | Syndax Pharmaceuticals, Inc. | Composés nouveaux et procédés pour les utiliser |
| US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
| WO2009067453A1 (fr) * | 2007-11-19 | 2009-05-28 | Syndax Pharmaceuticals, Inc. | Combinaisons d'inhibiteurs de la hdac et d'inhibiteurs de protéasomes |
| EP2249644A4 (fr) * | 2008-02-08 | 2012-05-30 | Poniard Pharmaceuticals Inc | Picoplatine et amrubicine utilisées dans le traitement du cancer du poumon |
| CA2729914A1 (fr) * | 2008-07-11 | 2010-01-14 | Novartis Ag | Combinaison de (a) un inhibiteur de phosphoinositide 3-kinase et de (b) un modulateur de voie ras/raf/mek |
| US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
| US8647067B2 (en) * | 2008-12-09 | 2014-02-11 | General Electric Company | Banked platform turbine blade |
| EP2370568B1 (fr) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mutations de mek conférant une résistance aux inhibiteurs de mek |
| CN102361557A (zh) * | 2009-03-26 | 2012-02-22 | Mapi医药公司 | 制备阿格列汀的方法 |
| CA2775125C (fr) * | 2009-09-23 | 2019-01-08 | Glaxosmithkline Llc | Combinaison d'un inhibiteur mek et d'un inhibiteur akt pour traiter le cancer |
| EP2480084B1 (fr) * | 2009-09-23 | 2014-11-12 | GlaxoSmithKline LLC | Combinaison pharmaceutique |
| AU2010298020B8 (en) | 2009-09-28 | 2013-10-10 | Glaxosmithkline Llc | Combination |
| DK4397376T3 (da) | 2009-10-16 | 2026-02-23 | Novartis Ag | Kombination der omfatter en mek-hæmmer og en b-raf-hæmmer |
| MX2012005758A (es) * | 2009-11-17 | 2012-06-19 | Glaxosmithkline Llc | Combinacion. |
| EP3028699B1 (fr) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Mutations braf conférant une résistance aux inhibiteurs de braf |
| EP2545187B1 (fr) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Procédés de diagnostic et de traitement du cancer chez des patients ayant ou développant une résistance à une première thérapie anticancéreuse |
| CA2794153C (fr) | 2010-03-25 | 2018-01-02 | Glaxosmithkline Llc | Derives d'indoline substitue comme inhibiteurs de perk |
| JP5858989B2 (ja) * | 2010-05-21 | 2016-02-10 | ノバルティス アーゲー | 組合せ |
| EP2608790A4 (fr) | 2010-08-26 | 2014-04-02 | Glaxosmithkline Llc | Combinaison pharmaceutique d'un inhibiteur du vegfr et d'un nhibiteur de mek, utile pour traiter le cancer |
| WO2012068339A2 (fr) * | 2010-11-17 | 2012-05-24 | Glaxosmithkline Llc | Procédés de traitement du cancer |
| ES2603479T3 (es) | 2010-12-20 | 2017-02-27 | Novartis Ag | Terapia de combinación que comprende gemcitabina para el tratamiento de cáncer pancreático |
| TWI505828B (zh) * | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| CA2846454A1 (fr) | 2011-08-31 | 2013-05-10 | Novartis Ag | Combinaisons synergiques d'inhibiteurs de pi3k et de mek |
| IN2014MN01754A (fr) | 2012-03-14 | 2015-07-03 | Lupin Ltd | |
| WO2013169858A1 (fr) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse |
| JP6335169B2 (ja) | 2012-08-17 | 2018-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | コビメチニブ及びメベムラフェニブを投与することを含むメラノーマの併用療法 |
| BR112015009134A2 (pt) * | 2012-10-25 | 2017-07-04 | Glaxosmithkline Llc | combinação |
| MA38121A1 (fr) | 2012-11-30 | 2016-10-31 | Glaxosmithkline Llc | Nouvelle composition pharmaceutique |
| CN104902896A (zh) | 2013-01-09 | 2015-09-09 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 组合 |
| US20140199728A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
| AR096433A1 (es) | 2013-05-28 | 2015-12-30 | Glaxosmithkline Intellectual Property (No 2) Ltd | Método de tratamiento del cáncer y uso |
| CN105658206A (zh) | 2013-06-03 | 2016-06-08 | 诺华股份有限公司 | 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合 |
| WO2015056180A1 (fr) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés d'indoline utilisés comme inhibiteurs de perk |
| WO2015059677A1 (fr) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Méthodes de traitement du cancer |
| MX2016007653A (es) | 2013-12-12 | 2016-10-13 | Novartis Ag | Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer. |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| WO2015105822A1 (fr) * | 2014-01-07 | 2015-07-16 | Glaxosmithkline Llc | Procédé de traitement du cancer |
| EP2913048A1 (fr) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Composition pharmaceutique comprenant de la trametinib |
| WO2016055935A1 (fr) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinaison d'inhibiteur de déméthylase 1 spécifique à la lysine et d'agoniste de thrombopoïétine |
| WO2016059602A2 (fr) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Méthodes de traitement du cancer et compositions associées |
| CN108135905A (zh) | 2015-08-28 | 2018-06-08 | 诺华股份有限公司 | 用于治疗癌症的cdk4/6抑制剂lee011、mek1/2抑制剂曲美替尼以及可任选还包括pi3k抑制剂byl719的组合 |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| US10861357B2 (en) * | 2015-11-13 | 2020-12-08 | Nike, Inc. | Athletic bib |
| RU2605400C1 (ru) * | 2015-11-13 | 2016-12-20 | ЗАО "Р-Фарм" | ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2 |
| WO2017098421A1 (fr) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Composés benzothiadiazine |
| WO2017153952A1 (fr) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | Dérivés de 5-sulfamoyl-2-hydroxybenzamide |
| KR101796684B1 (ko) * | 2016-05-19 | 2017-11-10 | 건국대학교 산학협력단 | 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법 |
| RU2627692C1 (ru) | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
| WO2019053617A1 (fr) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | Composés chimiques |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| WO2019180141A1 (fr) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinaisons de rogaratinib |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| AU2019372121A1 (en) | 2018-10-30 | 2021-05-27 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
| AR117206A1 (es) | 2018-11-30 | 2021-07-21 | Glaxosmithkline Ip Dev Ltd | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer |
| CA3124330A1 (fr) | 2018-12-21 | 2020-06-25 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugue anticorps-medicament et d'un inhibiteur de kinase |
| WO2020161654A1 (fr) * | 2019-02-06 | 2020-08-13 | Aurobindo Pharma Limited | Procédé de préparation d'un solvate d'acide acétique du tramétinib |
| AU2020299592A1 (en) | 2019-07-02 | 2022-02-17 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
| CN114502169A (zh) * | 2019-07-30 | 2022-05-13 | 埃德文斯公司 | 用于治疗中风的mek抑制剂 |
| EP4725489A2 (fr) | 2019-08-02 | 2026-04-15 | OneHealthCompany, Inc. | Traitement de cancers canins |
| US12268692B2 (en) | 2020-04-10 | 2025-04-08 | Postsurgical Therapeutics, Inc. | Combinatorial targeted therapy methods |
| US20230266321A1 (en) * | 2020-06-25 | 2023-08-24 | Icahn School Of Medicine At Mount Sinai | Live cell engagement assay |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| CN114853754B (zh) * | 2022-05-23 | 2023-04-18 | 云白药征武科技(上海)有限公司 | 一种硫代酰胺衍生物及其制备方法和应用 |
| AR129423A1 (es) | 2022-05-27 | 2024-08-21 | Viiv Healthcare Co | Compuestos útiles en la terapia contra el hiv |
| CN120813358A (zh) | 2023-04-06 | 2025-10-17 | 卫材R&D管理有限公司 | 用于治疗肿瘤的药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3139432A (en) | 1963-06-24 | 1964-06-30 | Mead Johnson & Co | Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones |
| DE4035479A1 (de) | 1990-11-08 | 1992-05-14 | Basf Ag | Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione |
| TR200101704T2 (tr) | 1998-12-15 | 2001-11-21 | Warner-Lambert Company | Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı |
| IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
| AU2203800A (en) | 1999-01-07 | 2000-07-24 | Warner-Lambert Company | Antiviral method using mek inhibitors |
| DE69924641D1 (de) | 1999-01-07 | 2005-05-12 | Warner Lambert Company Llc Mor | Behandlung von asthma anhand von mek-inhibitoren |
| DK1202724T3 (da) | 1999-07-16 | 2004-01-26 | Warner Lambert Co | Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| WO2002006520A1 (fr) | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Methode de criblage de compose regulant la transduction de signaux mek/erk et utilisation medicale dudit compose |
| WO2002006213A2 (fr) | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| US20040138285A1 (en) * | 2001-04-27 | 2004-07-15 | Makoto Okazaki | Chondrogenesis promoters |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
-
2005
- 2005-06-10 US US11/150,792 patent/US7378423B2/en active Active
-
2008
- 2008-03-21 US US12/053,133 patent/US20080312228A1/en not_active Abandoned
-
2009
- 2009-11-25 US US12/626,443 patent/US8835443B2/en active Active
-
2014
- 2014-08-07 US US14/454,404 patent/US20150183812A1/en not_active Abandoned
- 2014-11-28 BE BE2014C071C patent/BE2014C071I2/fr unknown
-
2016
- 2016-02-24 US US15/052,581 patent/US20170029418A1/en not_active Abandoned
-
2017
- 2017-10-27 US US15/795,973 patent/US20180273531A1/en not_active Abandoned
-
2019
- 2019-05-20 US US16/416,895 patent/US20200109139A1/en not_active Abandoned
-
2021
- 2021-12-08 US US17/545,664 patent/US20220380362A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100240613A1 (en) | 2010-09-23 |
| US20060014768A1 (en) | 2006-01-19 |
| US20180273531A1 (en) | 2018-09-27 |
| US8835443B2 (en) | 2014-09-16 |
| US20150183812A1 (en) | 2015-07-02 |
| US20080312228A1 (en) | 2008-12-18 |
| US20170029418A1 (en) | 2017-02-02 |
| US7378423B2 (en) | 2008-05-27 |
| US20200109139A1 (en) | 2020-04-09 |
| US20220380362A1 (en) | 2022-12-01 |